奥利司他:回顾其在肥胖的管理使用。

文章的细节

引用

复制到剪贴板

Hvizdos公里,马卡姆

奥利司他:回顾其在肥胖的管理使用。

药。1999年10月,58 (4):743 - 60。

PubMed ID

10551441 (在PubMed

]

文摘

奥利司他是小说non-systemic治疗肥胖。胃肠道药物抑制脂酶,防止大约30%的膳食脂肪的吸收。药效学研究研究证实,每日3次、每次120毫克剂量的奥利司他(每个主餐)是最优的。控制研究已经证实奥利司他120毫克每日3次、每次1年,结合hypocaloric饮食,使体重减少7.9到10.2%肥胖非糖尿病人。1研究减少肥胖的2型糖尿病患者的6.2%。奥利司他每日3次、每次120毫克明显比安慰剂更有效(也给结合hypocaloric饮食)在这些研究。毒品也显著比安慰剂更有效在2年的随机双盲研究涉及> 2000名患者。在第二年的治疗期间,患者从hypocaloric饮食转向eucaloric饮食,奥利司他接受恢复体重明显低于安慰剂组。奥利司他似乎改善非糖尿病肥胖病人的血脂水平,降低总胆固醇和低密度脂蛋白胆固醇的水平。在一项研究中患者的肥胖与2型糖尿病相关,奥利司他失去了更多的重量,提高了患者血清血脂水平与安慰剂组相比。 In addition, orlistat-treated patients achieved significant improvements in glycaemic control, enabling dosages of antidiabetic drugs to be reduced. Long term (1 to 2 years) tolerability data from 2038 patients in placebo-controlled trials revealed that the drug was generally well tolerated. The most commonly reported adverse events were related to decreased fat absorption and included oily faecal spotting, flatus with discharge, faecal urgency and oily stool. Systemic adverse events attributable to orlistat were negligible. CONCLUSION: Orlistat in conjunction with a hypocaloric diet has been shown to induce clinically significant weight loss in keeping with current guidelines for the management of obesity. This, together with its acceptable tolerability profile and lack of systemic adverse events, make it an attractive option in the treatment of obesity. The drug may have a positive effect on obesity-associated cardiovascular risk factors and type 2 diabetes.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

奥利司他